Question: What are the FDA priorities for compounding for 2019?
Answer:
This week, we will look at the statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new 2019 efforts to improve the quality of compounded drugs as they relate to compounding in a hospital pharmacy.
Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new 2019 efforts to improve the quality of compounded drugs
Statement (Opening)
Maintaining Quality Manufacturing and Compliance
Regulating Compounding from Bulk Drug Substances
Finalizing our Memorandum of Understanding with the States
Compounding by Hospital and Health Systems
Compounding by Hospital and Health Systems
“The agency recognizes that hospital and health system pharmacies are different than other pharmacies not owned by hospitals and from conventional manufacturers, and as such, have unique needs and challenges.
To that end, we plan to issue a revised draft guidance regarding hospital or health system compounding to provide further clarification on how the FDA intends to apply section 503A of the FD&C Act to drugs compounded at these facilities. Our revised policies will also provide guidance for hospital or health system pharmacies that might be considering registering as an outsourcing facility under section 503B.�
(Editor’s Note: Emphasis added.)
Additional Compounding Priorities
Editor’s Note: We will complete coverage of the FDA statements next week. Just a reminder, the complete statement can be obtained at:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements /ucm635182.htm
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|